Article
08 Apr 2026
That Free Trial Might Cost You: "Automatic Renewal" Litigation On The Rise In CA
CONTRIBUTING SINCE MARCH 2011
Buchanan Ingersoll & Rooney PC
With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
POPULAR TOPICS
Food, Drugs, Healthcare, Life Sciences
Cannabis & Hemp
International Law
Employment and HR
Energy and Natural Resources
Buchanan Ingersoll & Rooney PC are most popular:
- with readers working within the Environment & Waste Management industries
DETAILS
United States
+1 412 562 8800
Union Trust Building
501 Grant Street
Suite 200
Pittsburgh
United States
Contact Firm
COMPANY CONTENT
Article
06 Apr 2026
NIL Reform Efforts Gain Momentum: University Proposals And Federal Attention Signal Potential Structural Change
Article
06 Apr 2026
SEC Clarifies The Application Of The Securities Laws To Crypto Assets
Article
31 Mar 2026
CVS Caremark Settles FTC Insulin Pricing Lawsuit: Key Developments And Industry Impact
Article
30 Mar 2026
One Strike And You’re Out: Strikethrough Pricing And Perpetual Promotion Claims Surge
Article
27 Mar 2026
Antiboycott Compliance: Department Of The Treasury Publishes List Of Countries Requiring Cooperation With An International Boycott
Article
27 Mar 2026
Board Of Pharmacy Enforcement Is Accelerating: What Pharmacies And Industry Stakeholders Need To Do Now
Article
24 Mar 2026
Breaking Barriers: Mastering FDA Regulations, National Security, And Tariffs To Expand Your MedTech Company To The U.S.
Article
24 Mar 2026
Is The IRS Holding Your Money? How The Kwong Ruling Impacts Pandemic-Era Tax Refunds For Individuals, Companies, And Non-Profit Organizations
Article
23 Mar 2026
New Draft Guidance From FDA On Flavored Vape Products
Article
23 Mar 2026
The Consolidated Appropriations Act Of 2026: What Plan Sponsors And Pharmacies Need To Know And How To Use It
Article
23 Mar 2026
The Critical Obligation To Investigate And Report Overpayments: How To Avoid False Claims Act Liability
Article
19 Mar 2026
USTR Trade Policy Agenda: Trade Investigations Takeaways
Article
18 Mar 2026
Multi-Year Insurance Audits Of Physical Therapy Practices: Documentation, Medical Necessity, And The Growing Use Of Extrapolation
Article
18 Mar 2026
ERISA Class Action on Prescription Drug Benefits Gets Green Light — A Warning for Plan Sponsors
Article
16 Mar 2026
Tariff Duty Refunds: Most Recent Updates
Article
16 Mar 2026
IRS Releases Proposed Regulations To Modernize Broker-Dealer Payee Statements Regarding Digital Asset Sales
Article
13 Mar 2026
State Enforcement Against Pharmacy Benefit Managers Intensifies: Lessons From Louisiana And West Virginia
Article
10 Mar 2026
The Pendulum Swings Back: NLRB Formalizes Return To The 2020 Joint-Employer Standard
Article
10 Mar 2026
California's Record-Setting Enforcement Signals Heightened Privacy Oversight
AWARDS
